Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.

Sandro Mascena Gomes-FilhoEdmilson Ozorio Dos SantosEster Risério Matos BertoldiLuiza Coimbra ScalabriniVitor HeidrichBianca DazzaniElena LevantiniEduardo Moraes ReisDaniela Sanchez Bassères

Published in: Cellular oncology (Dordrecht) (2020)

From our data we conclude that AURKA and TPX2 may act as KRAS biomarkers in PDAC that can predict a worse prognosis, and that AURKA or TPX2 targeting in PDAC cells may reduce their transformed phenotype. These results indicate that AURKA and TPX2 may serve as promising targets to be explored for KRAS-mutant PDAC therapy.

Keyphrases

wild type
induced apoptosis
cell cycle arrest
diabetic rats
electronic health record
high glucose
stem cells
cancer therapy
oxidative stress
mesenchymal stem cells
protein kinase
drug induced
cell death
human health
pi k akt
replacement therapy